Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...
In November, virologist Beata Halassy announced to the world that she had cured her own breast cancer using a treatment ...
Research and development (R&D) expenses for the fourth quarter and full year 2024 were $1.3 million and $10.5 million, respectively, compared to $9.7 million and $40.0 million for the same periods in ...
FDA’s Rare Disease Innovation Hub Releases Strategic Agenda: Implications for Stakeholders in 2025
In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...
Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Neuren Pharmaceuticals (ASX: NEU) has been granted the chance to talk to the U.S. Food and Drug Administration (FDA) about some of the positive indicators that may be expected from its upcoming Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback